Drug evaluation: AMG-531 for the treatment of thrombocytopenias

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

Original languageEnglish (US)
Pages (from-to)834-841
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Issue number9
StatePublished - Sep 2006

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Drug evaluation: AMG-531 for the treatment of thrombocytopenias'. Together they form a unique fingerprint.

Cite this